Measurement of serum and tissue des-γ-carboxyprothrombin in resectable hepatocellular carcinoma

Anticancer Research

Volumn 28, Issue 4 B, 2008, Pages 2219-2224

  Xiang, Can Hong ^a,b   Zhang, Wei ^a,c   Inagaki, Yoshinori ^a   Zhang, Ke Ming ^a,b   Nakano, Yasuhiro ^d   Kokudo, Norihiro ^a   Sugawara, Asuhiko ^a   Dong, Jia Hong ^b   Nakata, Munehiro ^d   Tang, Wei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

Dei carboxyprothrombin; Electrochemiluminescence immunoassay; Hepatocellular carcinoma

Indexed keywords

DECARBOXYPROTHROMBIN;

ADULT; ARTICLE; CHEMOLUMINESCENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEOMICS; TISSUE LEVEL;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN;

EID: 49049122240     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Umemura T and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 37: S95-S100, 2007.
2. Okuda K: Epidemiology. In: Diagnosis and Treatment of Hepatocellular Carcinoma. Livraghi T, Makuuchi M, Buscarini L (eds.). London, UK: Greenwich Medical Media, pp. 3-15, 1997.
3. Ganrot PO and Nilehn J-E: Plasma prothrombin during treatment with dicumarol: II. Demonstration of an abnormal prothrombin fraction. Scand J Clin Lab Invest 22: 23-28, 1968.
4. Nelsestuen GL and Suttie JW: The purification and properties of an abnormal prothrombin protein produced by dicumarol-treated cows. A comparison to normal prothrombin. J Biol Chem 247: 8176-8182, 1972.
5. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS and Furie B: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310: 1427-1431, 1984.
6. Nakao A, Suzuki Y, Isshiki K, Kimura Y, Takeda S, Kishimoto W, Nonami T, Harada A and Takagi H: Clinical evaluation of plasma abnormal prothrombin(des-γ-carboxy prothrombin) in hepatobiliary malignancies and other disease. Am J Gastroenterol 86: 62-66, 1991.
7. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S and Omata M: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91: 561-569, 2001.
8. Gotoh M, Nakatani T, Masuda T, Mizuguchi Y, Sakamoto M, Tsuchiya R, Kato H and Furuta K: Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma- carboxyprothrombin. Jpn J Clin Oncol 33: 522-526, 2003.
9. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY and Han KH: PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 72(Suppl 1): 52-57, 2007.
10. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ and Lok AS: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37: 1114-1121, 2003.
11. Ono M, Ohta H, Ohhira M, Sekiya C and Namiki M: Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma. Am J Gastroenterol 85: 1149-1154, 1990.
12. Yamagata H, Nakanishi T, Furukawa M, Okuda H and Obata H: Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue. J Gastroenterol Hepatol 10: 8-13, 1995.
13. Shah DV, Zhang P, Engelke JA, Bach AU and Suttie JW: Vitamin K-dependent carboxylase activity, prothrombin mRNA, and prothrombin production in two cultured rat hepatoma cell lines. Thromb Res 70: 365-373, 1993.
14. Fujioka M, Nakashima Y, Nakashima O and Kojiro M: Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 34: 1128-1134, 2001.
15. Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S and Makuuchi M: Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 22: 969-975, 2003.
16. Tang W, Kokudo N, Sugawara Y, Guo Q, Imamura H, Sano K, Karako H, Qu X, Nakata M and Makuuchi M: Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep 13: 25-30, 2005.
17. Yuan LW, Tang W, Kokudo N, Sugawara Y, Karako H, Hasegawa K, Aoki T, Kyoden Y, Deli G, Li YG and Makuuchi M: Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma. Oncol Rep 12: 269-273, 2004.
18. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 4th edition. Tokyo, Japan: Kanehara 2000.
19. Sobin LH and Wittekind C: TNM Classification of Malignant Tumors. 5th edition. New York: Wiley-Liss 1997.
20. Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P and Kutner M: Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med 90: 185-187, 1979.
21. Van Thiel DH, Hagler NG, Schade RR, Skolnick ML, Heyl AP, Rosenblum E, Gavaler JS and Penkrot RJ: In vivo hepatic volume determination using sonography and computed tomography. Gastroenterology 88: 1812-1817, 1985.
22. Nakagawa T, Seki T, Shiro T, Wakabayashi M, Imamura M, Itoh T, Tamai T, Nishimura A, Yamashiki N, Matsuzaki K, Sakaida N, Inoue K and Okamura A: Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma. Int J Oncol 14: 281-286, 1999.
23. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M and Nakano M: Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 88: 544-549, 2000.
24. Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Tameda Y and Nakano T: Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. Int J Mol Med 9: 245-250, 2002.
25. Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, Arisawa K, Ishibashi H, Koga M, Sata M and Yano M: The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 98: 2671-2677, 2003.
26. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E and Shiratori Y: Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101: 2038-2043, 2006.
27. Miyaaki H, Nakashima O, Kurogi M, Eguchi K and Kojiro M: Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 42: 962-968, 2007.
28. Huisse MG, Leclercq M, Belghiti J, Flejou JF, Suttie JW, Bezeaud A, Stafford DW and Guillin MC: Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas. Cancer 74: 1533-1541, 1994
29. Miyakawa T, Kajiwara Y, Shirahata A, Okamoto K, Itoh H and Ohsato K: Vitamin K contents in liver tissue of hepatocellular carcinoma patients. Jpn J Cancer Res 91: 68-74, 2000.